Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vudalimab + SOC in mCSPC
NCT05733351Phase 1Terminated
- Sponsor
- Emory University
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vudalimab in prostate cancer (PCa) (3 cohorts), sponsored by Emory University. Primary endpoints: Incidence of Adverse Events and Radiographic Progression-Free Survival up to 3 years. Started Aug 2023; status: terminated.
02
Drugs
vudalimab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05733351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733351.